Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isbogrel SCHEMBL7766547 | 1.00 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| (E)-Isbogrel SCHEMBL4061 | 1.00 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| (E)-Isbogrel SCHEMBL10632111 | 0.99 | TBXAS1 (0.97) | TBXAS1TBXA2R | |
| SCHEMBL10616376 | 0.99 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| (E)-Isbogrel SCHEMBL10632121 | 0.99 | TBXAS1 (0.97) | TBXAS1TBXA2R | |
| SCHEMBL10616364 | 0.99 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| Isbogrel SCHEMBL10632116 | 0.99 | TBXAS1 (0.97) | TBXAS1TBXA2R | |
| SCHEMBL10634966 | 0.99 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| SCHEMBL10634973 | 0.99 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| SCHEMBL10680940 | 0.99 | TBXAS1 (1.00) | TBXAS1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | claimed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | claimed |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2018-05-10 | — | — | US | claimed |
| US-20160368895-A1 | PULMONARY HYPERTENSION TREATING AGENT | THE UNIVERSITY OF TOKYO (JP) | 2016-12-22 | — | — | US | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5830432-A | Phospholipid drug derivatives | AMUR PHARMACUTICALS, INC. (US) | 1998-11-03 | — | — | US | claimed |
| WO-1998043676-A1 | PHOSPHOLIPID DRUG DERIVATIVES | AMUR PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| US-4925869-A | REACTIVATING ENZYME ACETYLCHOLINESTERASE INHIBITED BY LETHAL DOSE OF SOMAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | claimed |
| US-4908380-A | Substituted 1,3-dioxane ether derivative; thromboxane A2 inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| EP-0098690-B1 | VINYL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1987-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | TBXAS1 233/4885TBXA2R 52/4885 |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, NOS3 | TBXAS1 540/4885TBXA2R 180/4885 |
| US-20160368895-A1 | PULMONARY HYPERTENSION TREATING AGENT | PTGIR, AGTR1, PTGER1 | TBXAS1 104/4885TBXA2R 6/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | TBXAS1 220/4885TBXA2R 2982/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | TBXAS1 612/4885TBXA2R 181/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | TBXAS1 233/4885TBXA2R 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.